Sign up USA
Proactive Investors - Run By Investors For Investors

Medicenna Therapeutics nudges higher as it doses first patient with brain cancer therapy

Immunotherapy MDNA55 is the group's lead candidate...
Medicenna Therapeutics nudges higher as it doses first  patient with brain cancer therapy
The study will be conducted in around ten US sites..

A subsidiary of Medicenna Therapeutics Corp (CVE:MDNA) has treated the first patient in its Phase 2b clinical trial of its lead candidate to treat the most common and uniformly fatal form of brain cancer.

Immunotherapy MDNA55 is the subsidiary's lead candidate and is for recurrent glioblastoma (rGB).

Significant milestone..

"Dosing the first patient in this clinical trial is a significant milestone for the company as we look to build upon the promising results from earlier studies with MDNA55," said Dr Fahar Merchant, chairman and chief executive of Medicenna.

"We are pleased to be working with leading neuro-surgical centers in the US as we explore the benefits of MDNA55 for the treatment of rGB and other types of brain cancer."

The study is a multi-center, single-arm, open-label, Phase 2 investigation and will enroll around 43 adult patients with glioblastoma who have progressed or recurred following previous therapy.

Top line results expected in 2018..

The study will be conducted in around ten US sites. Patient enrolment is expected to be completed before the end of 2017 with top-line results anticipated in the first half of 2018.

MDNA55 has received 'fast track designation' from the FDA and orphan drug status from both the FDA and EMA.

Earlier results from three Phase 1 and 2a clinical trials in 66 patients with glioblastoma showed potent anti-tumor effects without drug-related systemic toxicity in the majority of patients.

Shares added 1.79% in early deals at $2.85.


Register here to be notified of future PROAC Company articles
View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

February 20 2017
One particular development of note is Cello Pulsar, a social media analytics tool that has, according to the experts, the potential to be a real winner.
White board with marketing ideas
March 13 2017
There was a bit of a wobble in the run-up to the Brexit vote and shortly after it, but the group's 'buy, build & grow' strategy is taking shape
Digital marketing
March 28 2017
Michael Karg, Ebiquity’s CEO, said:“We have already made good progress with our growth acceleration plan, which will replicate our service offering across key territories, further strengthening our ability to service global clients.”
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use